title: RTI-274
text: # RTI-274
  
  RTI(-4229)-274, or 2β-((3,4-Methyl​enedioxy​phenoxy)methyl)-3α-(4-fluorophenyl)​nortropane is a phenyltropane homologue of paroxetine developed by the group led by F Ivy Carroll in the 1990s.
  
  ## Introduction
  
  Very few esters of phenyltropanes are actually known to have been reported.
  
  NS2330 and NS2359 both have α,β stereochemistry.
  
  NS2214 appears to have been abandoned now, RTI-336 was their latest compound.
  
  RTI decided that they wanted to make all 8 stereoisomers of the phenyltropane paroxetine homolog.
  
  MAT IC50 (nM) Nor/tropane-Paroxetine Hybrids :
  
  | Compound | Compound | $[^3H]CFT$ | $[^3H]Paroxetine$ | $[^3H]Nisoxetine$ |
  | - | - | - | - | - |
  | Paroxetine | Paroxetine | ? → 623 | ? → 0.28 | ? → 535 |
  | R | "β,β" | 308 → 835 | 294 → 480 | 5,300 → 37,400 |
  | R | α,β | 172 → 142 | 52.9 → 90 | 26,600 → 2,500 |
  | R | β,α | 3.01 → 3.86 | 422 → 5.62 | 123 → 14.4 |
  | S | "β,β" | 1,050 → 1,210 | 88.1 → 424 | 27,600 → 17,300 |
  | S | α,β | 1,500 → 27.6 | 447→ 55.8 | 2,916 → 1,690 |
  | S | β,α | 298 → 407 | 178 → 19 | 12,400 → 1,990 |
  
  * N-demethylating the S-α,β (1S,2S,3R) isomer resulted in a 54-fold increase in DAT IC50.
  
  In the case of nocaine it is understood that the SR enantiomer is the one that should be demethylated if it is wanted to improve DAT affinity.
  
  That is the same enantiomer that is used in the production of paroxetine.
  
  ## Skeletal rearrangement
  
  Four years later some unrelated authors cited a skeletal rearrangement accounts for this. Diagram
  
  Notice that they are not only interested in ethers, but nitrogen containing Nu's ("TRODAT")
  
  The metal is called "Technetium" and is bound by a chelating agent.
  
  The authors state that at first the acid is halogenated, the amide is prepared, and reduced.
  
  ## Erratum
  
  (a) (1) 1-chloroethyl chloroformate, 1,2-dichloroethane, reflux; (2) MeOH reflux; (b) p-toluenesulfonyl chloride, triethylamine; (c) $LiAlH_4,$ THF, rt; (d) trifluoromethanesulfonic anhydride, pyridine, $CH_2Cl_2;$ (e) Na, sesamol, THF; (f) 5% Na/Hg amalgam, $Na_2HPO_4,$ MeOH.
  
  MAT IC50 $(K_i)$ N-Methyl → De-methyl :
  
  | Compound | $[^3H]CFT$ | $[^3H]Nisoxetine$ | $[^3H]paroxetine$ |
  | - | - | - | - |
  | R-β,β | ? → 3 | ? → 2 (0.2) | ? → 6 (4) |
  | S-β,β | ? → ? | ? → ? (?) | ? → ? (?) |
  | R-"nonane" | 308 → 835 | 294 (27) → 480 (44) | 5,300 (3200) → 37,400 (22,500) |
  | S-"nonane" | 1050 → 1210 | 88 (8) → 424 (39) | 27,600 (16,600) → 17,300 (10,400) |
  
  To solve the problem of the unexpected aza-bicyclo[3.2.2]nonane rearrangement product, the original synthesis had to be modified as follows; WIN 35428 was N-demethylated and then the NH amine was reacted with a suitable protecting group so that N is no longer nucleophilic. In their case they used a tosyl.
  
  